Anyone can get colorectal cancer. Doctors often don't know why it happens, but they know some of the things that make people more likely to get it. These include: Age. The disease is most common ...
Natera has reported the latest data from the Phase III CALGB (Alliance)/SWOG 80702 study, indicating that Signatera, a ...
A groundbreaking blood test for colorectal cancer screening has received approval from the U.S. Food and Drug Administration (FDA), offering the potential to revolutionize early detection for one ...
Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in the PI3K ...
Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...
A colorectal cancer doctor is making the case for butting into your family’s business. Dr. Parul Shukla, a colon and rectal surgeon with Northwell Health, said there’s a key piece of advice he ...
News Medical on MSN1d
Dual-targeted therapy plus chemo boosts response rate in BRAF-mutated metastatic colorectal cancerPatients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback